The announcement comes months after Ayuvya’s appearance on Shark Tank India Season 5, where the brand impressed the Sharks with its ₹51.5 crore revenue in FY25 and strong presence across Tier-3 and Tier-4 India. While appreciating the company’s growth, the Sharks questioned the lack of clinical validation behind its formulations, with Kunal Bahl remarking, “Pehle vishwas banao” (Build trust first). The feedback prompted the company to invest in registered clinical research to strengthen the scientific evidence supporting its products.

The study also addresses a much larger gap in the healthcare conversation. According to the National Family Health Survey (NFHS-5), nearly 18.7% of women and 16.2% of men aged 15-49 in India have a Body Mass Index (BMI) below 18.5, classifying them as underweight. Globally, research published in The Lancet estimates that more than 390 million adults are underweight, with India accounting for one of the world’s largest underweight populations. Despite these numbers, healthy weight gain remains a relatively under-researched area, with limited clinical evidence supporting interventions specifically designed for this population.

Against this backdrop, Ayuvya’s clinical study, registered with the Clinical Trials Registry-India (CTRI/2026/02/103541) under the Indian Council of Medical Research (ICMR), enrolled 110 adults aged 18 to 35 years with poor appetite and a BMI below 20 across two clinical sites in Bengaluru. Conducted over 45 days, the open-label, single-arm study evaluated changes in appetite, body weight, BMI, nutritional status, gastrointestinal comfort, quality of life, and safety parameters, including liver function. A total of 106 participants (96.4%) completed the study.

According to Ms. Astha Jain, Co-Founder of Ayuvya, “When we appeared on Shark Tank India, the Sharks challenged us to build stronger scientific credibility for our products, and we believed that was fair feedback.  At the same time, we realised there is another conversation that deserves more attention. While obesity has dominated public discourse for decades, millions of people continue to struggle with being underweight, poor appetite, and healthy weight gain. We wanted to respond to both challenges by investing in clinical research that strengthens trust while contributing evidence to an often-overlooked area of health. According to the investigators, participants using the combination of AYUVYA i-Gain+ Tablets and AYUVYA Lets Gain Powder demonstrated improvements in appetite, body weight, BMI, nutritional status, gastrointestinal health, and overall quality of life while maintaining a favourable safety and tolerability profile throughout the study period. The study reported up to a 5.90% improvement in body weight and up to a 7.47% improvement in BMI.

The company aims to provide clinical validation for every major Ayuvya product, reinforcing its commitment to scientific research and evidence-based Ayurvedic formulations. Through this approach, it seeks to build consumer trust and establish Ayuvya as a household name synonymous with clinically backed wellness solutions.